How long does bone marrow suppression due to venetoclax/venetoclax usually last?

Venetoclax/Venetoclax, as an oral B-cell lymphoma-2 (BCL-2) protein inhibitor, is often used in combination with other drugs for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, while taking venetoclax, patients may face myelosuppression, a condition in which the drug affects the bone marrow's ability to produce blood cells, which is often accompanied by an increased risk of infection and prolonged hospitalization.

The duration of bone marrow suppression has individual differences and is affected by the patient's personal characteristics, the treatment regimen received, and external intervention factors. Typically, symptoms of myelosuppression may appear within weeks of starting treatment and may persist for weeks or even months. In some extreme cases, the effects of myelosuppression on blood cell production may be more lasting, leading to adverse effects such as anemia, thrombocytopenia, or leukopenia. Studies have shown that shortening the medication cycle of venetoclax to 14 days can reduce the risk of related complications without reducing the efficacy of AML treatment.

During treatment, doctors will regularly monitor the patient's blood cell counts to ensure that their blood conditions remain within normal limits. When symptoms of myelosuppression are discovered, doctors may adjust the medication regimen or even suspend the use of venetoclax to reduce its adverse effects on the bone marrow.

If patients experience any discomfort or abnormal reactions while using venetoclax, especially symptoms related to blood cell reduction, such as persistent fatigue, easy bleeding, susceptibility to infection, or difficulty breathing, they should seek medical attention immediately and contact their attending physician.